Comparing SonoVue With Sonazoid Using CEUS-LIRADS in HCC

Comparing SonoVue With Sonazoid in the Performance of Contrast Enhanced Ultrasound The Liver Imaging Reporting and Data System (CEUS-LIRADS) in Diagosing HCC: a Prospective Blind Study

The new version of CEUS LI-RADS published at 2018(version 2017). In this study, the investigators aim to investigate the diagnosing performance of CEUS LI-RADS by administrating different contrast agents (SonoVue/ Sonazoid).

Independent radiologists from department of ultrasound will report their diagnosing results according to CEUS LI-RADS version 2017 without getting any information about patients. The researcher of this subject will collect all results and evaluated the sensitivity and specificity of CEUS LI-RADS and the diagnosing performance with different contrast agents.

Inclusion Criteria:

• Patients at risk for HCC with focal liver lesion on conventional ultrasound.
• history of cirrhosis.
• historty of HBV infection.

Exclusion Criteria:

• systemic therapy with sorafenib
• pretreat lesion
• patients don't sign the informed consent.